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Abstract
Background: Depression occurs in up to 50% of patients after stroke and limits rehabilitation and recovery. Mood
disorders are also highly prevalent in carers; their mental health intertwined with the physical and mental
wellbeing of the person they are caring for. We argue that working with families, rather than patients alone may
improve the treatment of depression in both patients and their carers enhancing the mental wellbeing and quality
of life of both.
Methods: A single blind cluster randomised controlled trial to evaluate whether families after stroke who are
treated with the Depression Recognition and Treatment package (DepReT-Stroke) in addition to treatment as usual
(TAU) show improved mental well being compared to those families who receive only TAU. We aim to recruit one
hundred and twenty-six families (63 in each group). The DepReT-Stroke intervention will help families to consider
the various treatment options for depression, make choices about which are likely to fit best with their lives and
support them in the use of self-help therapies (e.g. computerised Cognitive Behavioural Therapy or exercise). An
essential component of the DepReT-Stroke package will be to help people adhere to their chosen treatment(s).
The primary outcome will be the Mental Component Subscale of the SF-36 assessed at baseline and again six
months post intervention. Effectiveness of the intervention will be determined using analysis of co-variance;
comparing the mean change in MCS scores from baseline to six months follow-up adjusting for the clustering
effects of baseline scores and family. An economic evaluation of the intervention will help us determine whether
the intervention represents a cost-effective use of resources.
Discussion: Depression both for patients and their carers is common after stroke. Our Depression Recognition and
Treatment package (DepReT-stroke) may help clinicians be more effective at detecting and managing a common
co-morbidity that limits rehabilitation and recovery.
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Stroke and depression
Stroke is a leading cause of disability, requiring consid-
erable adjustment in the lives of those affected. Depres-
sion after stroke (Post Stroke Depression, PSD) is
common and, compared with non-depressed stroke
patients, is associated with worse long-term outcomes
[1-3]. Depression is a distressing illness and is associated
with a substantial reduction in quality of life and
increased risk of suicide [4-6]. PSD occurs in up to 50%
of all stroke survivors [7,8] with prevalence peaking
approximately six months after the vascular event
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is often inadequately diagnosed and treated, despite an
evidence base for effective treatments [9]. Adherence
with treatment is often poor, especially when prescribed
without taking patient preferences into account. In Eng-
land, stroke results in an estimated total annual cost of
£7 billion [10,11].
Treatment for depression
There is established efficacy for a range of treatments
for depression that include medication, psychological
treatments (such as cognitive behavioural therapy
(CBT)) and exercise [12]. Antidepressants are effective
in PSD both in terms of improving mood and enhancing
stroke recovery [8,13]. Problems with the pharmacologi-
cal treatment of depression seen in the general popula-
tion are mirrored in patients with stroke. This includes
inadequate prescriptions in terms of dose and duration
[14,15] and treatment non-adherence: 44% within 3
months of starting treatment [16]. Generally patients
express a preference for psychological over pharmacolo-
gical treatments[17]. Cognitive Behaviour Therapy
(CBT) with its problem-focused approach may be parti-
cularly suited to the treatment of PSD [18] being as
effective as medication with about 50% of patients
experiencing clinically meaningful improvement [19].
CBT is the treatment of choice for mild depression and
is also recommended for moderate to severe depression
or where patients refuse antidepressant treatment. Popu-
lation studies have shown clear associations between
physical exercise and mental health in older adults [20].
Recent trials in patients with PSD have shown exercise
to be a feasible intervention that can significantly
improve the patient’s Activities of Daily Living and per-
ceived physical health as well as help relieve depressive
symptoms [20-23].
The impact of stroke on carers
Many stroke survivors can live in the community, pro-
vided they have support and are cared for by a family
member [24]. Care giving to a family member who has
survived a stroke is demanding [25,26] and is associated
with an increased risk of depression in the carer [27].
Patients’ poor motor function, impaired memory and
behaviour changes seem to have the most profound
impact on carers’ mental health [26-28]. Three months
after the stroke up to 40% of carers will experience a
depression, without a noticeable reduction in the preva-
l e n c e1 2t o1 8m o n t h sa f t e rthe event [27,29], with
some evidence suggesting that care givers were in fact
more likely to be depressed than the stroke sufferers
themselves [27].
Study rationale
The mental health of carers is intertwined with the
mental health and disease presentation of stroke
patients. Literature reviews suggest that stroke rehabili-
tation should focus on the family rather than the patient
alone [30,31]. Stroke survivors whose families act as
partners in the rehabilitation process achieve better out-
comes [32] and spouses of stroke survivors can benefit
significantly in physical and mental well being from
nurse-led support and education programmes [33].
Therefore, working with families, rather than patients
alone, may have an important role to play in enhancing
the mental wellbeing of both group.
While effective management of PSD enhances stroke
recovery and improves outcomes [34,35], PSD is often
not recognised [35] and consequently treatment is not
given. The Healthcare Commission [36] reports that fol-
lowing discharge from hospital, fewer than 30% of
stroke patients with emotional problems (such as
depression and crying) state they ‘get enough help’ from
the NHS.
We aim to maximise the effectiveness of otherwise
established depression treatments in stroke patients
and/or carers by enabling them to make informed
choices when selecting their depression treatment (i.e.
medication, psychological treatments and exercise) and
by continuing to support them in structured (adherence)
sessions with a trained nurse conducted in their home.
The participants’ experience of the treatment package
will be explored by semi-structured interviews with peo-
ple with stroke, carers and involved health professionals
to understand which aspects of the package are seen as
most/least helpful and uncovering any potential barriers
to routine use in the health service. This pragmatic
approach will yield a much needed evidence based inter-
vention that tests the efficacy mechanism for the pre-
vention, recognition and treatment of depression in
families after stroke [37].
The project will enable us to develop a package that
will equip nurses (and other health workers) in the com-
munity to work effectively and productively in addres-
sing the burden of depression in people with stroke and
their carers. Tackling the burden of depression in
families after stroke may help ensure optimal disease
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quality of life for people with stroke and their carers.
An economic evaluation of the intervention will help us
determine whether the intervention represents a cost-
effective use of scarce NHS resources.
Methods/design
Trial objectives
To evaluate whether families who receive a Depression
Recognition and Treatment package (DepReT-Stroke) in
addition to treatment as usual (TAU), show improved
mental wellbeing compared to those who receive TAU.
Secondary objectives are to evaluate whether families
who receive DepReT-Stroke show improvements in
mood, knowledge about depression, adherence to treat-
ment and reduced carer burden compared to families
receiving TAU; the process experience of DepReT-Stroke
from the point of view of people with stroke, their carers
and nurses delivering the intervention; the cost effective-
ness of DepReT-Stroke in comparison to TAU.
Summary of trial design
A single-blind, randomised controlled, cluster trial
design to compare DepReT-Stroke with TAU in the
treatment of depression in families living with stroke.
Primary and Secondary Outcome measures
The primary outcome for DepReT-Stroke is change in
the mental wellbeing of both patients and carers as mea-
sured by the Mental Component Summary (MCS) score
of the Medical Outcome Study (MOS) 36 Item Short
Form Health Survey (SF-36) version 2.
Secondary outcome measures for both the patient and
their primary carer comprise: Hospital Anxiety &
Depression Scale (HADS); Knowledge about Depression
and Mania Inventory (KDMI); Beliefs about Medicines
Questionnaire (BMQ); Zarit Carer Burden Inventory
(ZCBI) (only to be completed by the carer); EuroQol
quality of life questionnaire (EQ-5D); Levels of resource
use associated with DepReT-Stroke and TAU
Trial Participants
The study population are families living with stroke that
have co-occurring depression in the patient, the carer or
both. We will recruit ‘families’ (defined as a person suf-
fering from stroke and their self declared primary carer)
from the Norfolk and Norwich University Hospitals
(NNUH) NHS Trust Stroke Register [38].
Inclusion Criteria
The inclusion criteria for DepReT-Stroke are patients
diagnosed with ischaemic or haemorrhagic stroke, con-
firmed by computerised tomography and listed on the
NNUH stroke register; three months post stroke; living
at home for not less than two weeks; has a self defined
‘primary carer’; patient and/or carer scores ≥8o nt h e
HADS; over 18 years of age (no upper age limit).
At three month post stroke the potential complications
arising from the acute event should have settled and the
patient is more likely to be relatively stable, both medi-
cally and psychologically. We chose at least two weeks
post discharge from hospital/rehabilitation unit because
it can be expected that a sense of routine is beginning to
be established by the family by this time. According to
the Healthcare Commission’s report [36] patients ‘...can
feel abandoned when they lose the emotional and practi-
cal support they receive in hospital...’ Once patients have
settled at home, they, and their families, may welcome
further contact with specialist stoke staff.
Exclusion Criteria
Families living with stroke will not be included in the
trial if either the patient or the carer has a serious or
unstable medical condition (e.g. advanced/incurable can-
cer; severe co-morbidity or severe unpredictable pain);
psychosis or other severe mental illness; suicidal
thoughts or ideation or dementia. We will also exclude
families if either the patient or carer is institutionalised
(e.g. care home resident) or is participating in any other
research concerning stroke or depression
Screening
The NNUH Stroke Register from 1
st January 2005 will be
cross referenced with the hospital Patient Administration
System (PAS) records to exclude patients who have sub-
sequently died, have evidence of serious/unstable medical
conditions or severe mental illness or as far as we can tell
are not eligible to be included in the study for any other
reason (i.e. discharge destination of residential or nursing
home). A further screen for mortality will be conducted
by telephoning the patient’s GP to request information
on their status. The remaining patients and their carers
will be written to by the Consultant Stroke Physician
who treated them whilst they were in hospital to invite
them to participate in the study. The letter contains brief
information about the trial, what it involves and includes
a check list on the essential inclusion criteria (i.e. that the
patient has a self-defined ‘primary carer’ and that either
the patient and/or carer consider they are depressed
[39]). If the patient and carer are interested in the study,
they will be asked to complete a reply slip and send it
back to the patient’s consultant in the free post envelope
provided. The reply slip requests information on the
name of the person who wishes to be contacted by the
research team and whether the patient has any difficulties
with speaking.
Potential participants/carers will be telephoned by a
research nurse who will make further enquiries on trial
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patient and/or carer as appropriate. If either the patient
or carer has a HADS score ≥8 and they still wish to par-
t i c i p a t ei nt h et r i a l ,t h en u r s ew i l la r r a n g ead a t ef o ra
Research Associate (RA) from the study team to visit
them at home. All those approached will be asked
whether they wish to receive written information about
recognising, preventing and treating depression.
Informed Consent
A research assistant from the study team will visit the
family and make a final check on trial eligibility. Written
and verbal versions of a Participant Information Leaflet
(PIL) will then be presented to the person with stroke
and their carer detailing the exact nature of the study.
In particular the RA will explain the randomised alloca-
tion element of the trial. It will be made clear that the
family is free to withdraw from the study at any time
for any reason without prejudice to future care, and
with no obligation to give the reason for withdrawal.
The patient and carer will be allowed as much time as
they wish to consider the information and ask questions.
If required, the RA will facilitate opportunities to ques-
tion other members of the research team, their General
Practitioner (GP) or other independent parties to decide
whether they will participate in the study. This may
mean that the RA has to arrange a subsequent home
v i s i ta tal a t e rd a t ea f t e rp r ior agreement and arrange-
ment with the patient and the carer.
We will seek consent from the person with stroke
whenever possible. An additional PIL has been designed
to accommodate people with aphasia and the RA will be
trained in effective strategies for communication with
this patient group. Written Informed Consent will be
obtained from the person with stroke and their carer if
they were eligible and agreed to participate. In case of
mental incapacity to give informed consent, we will seek
approval of an appropriate personal consultee (which we
expect will be the carer in most instances). Written infor-
mation will be provided to potential consultees describ-
ing this role under section 32 of the Mental Capacity Act
[40] and information about the research similar to that
given to participants able to consent for themselves.
Baseline measures
The RA who is masked to treatment allocation and
trained to administer questionnaires in a standardised
way will collect baseline data after informed consent is
obtained. The following data will be collected:
Mental Component Summary of the 36 Item Short Form
Health Survey (SF-36v2)
The SF36 is a self-report multidimensional measure of
health-related quality of life and wellbeing [41]. The psy-
chometric properties of the SF36 have been well
established. The scales of the SF-36v2 address eight
health domains and two summary measures are pro-
vided: a physical component summary score (PCS), and
a mental component summary score (MCS). The MCS
was selected as the main quality of life (QoL) outcome
measure for this trial as it has been shown to have good
sensitivity to change [42]
Hospital Anxiety and Depression Scale (HADS)
The HADS is a self screening questionnaire for depres-
sion and anxiety [43]. It consists of 14 questions, seven
for anxiety and seven for depression. Although it was
designed for hospital General Medical Outpatients, it
has been extensively used in Primary Care settings [44].
Knowledge of Depression Multiple Choice Question Test
(KD-MCQ)
The KD-MCQ is a 27-item, multiple choice validated
instrument to measure educational domains of knowl-
edge in people suffering from depression [45]. A higher
score indicates greater knowledge about depression.
Beliefs about Medicines Questionnaire (BMQ)
The BMQ consists of two five items scales assessing
peoples’ beliefs about the necessity of prescribed medi-
cation for controlling their illness and potential conse-
quences of taking it [46]. Participants rate each item on
a five point Likert-type scale. A higher score indicates
more positive attitudes towards medication.
Zarit Carer Burden Inventory - Short version (ZCBI-s)
The ZCBI is a validated instrument used to measure the
distress experienced by caregivers of elderly or disabled
persons [47]. The questionnaire comprises 22 items
about the impact of the person’s disabilities on care-
giver’s physical and emotional health. A truncated ver-
sion of this instrument (12 items) has been developed
which produces results comparable to the full question-
naire [48]. This short version has been selected to
reduce the time burden imposed on study participants
when administering the questionnaire.
The EuroQol EQ-5D questionnaire (EQ-5D)
T h eE Q - 5 D ,f r o mw h i c hQ u a l i t yA d j u s t e dL i f eY e a r s
(QALYs) can be derived is an established, standardised
health-related quality of life instrument used extensively
in clinical studies [49]. It comprises five items covering
the domains of mobility, self-care, usual activity, pain/
discomfort and anxiety/depression. The EQ-5D is cogni-
tively simple, taking only a few minutes to complete.
Instructions to respondents are included in the
questionnaire.
The Client Service Receipt Inventory (CSRI) amended for use
in older people
The CSRI [50] collects retrospective information about
the interviewee’s use of health and social care services,
accommodation and living situations, income, employ-
ment and benefits. An adapted version of this instru-
ment will be used to collect information on trial
Gray et al. Trials 2011, 12:105
http://www.trialsjournal.com/content/12/1/105
Page 4 of 8participants’ use of health services and associated costs
incurred over the study period.
Potential confounding factors
We will measure a number of potential confounding
factors at baseline including, stroke severity (using the
Stroke Impact Scale [51]), continence (using the Barthel
Activities of Daily Living Index - items 5, 6 and 7 [52]),
cognitive function (using the General Practitioner
Assessment of Cognition [53]), behavioural disturbance
(using the Behaviour and Mood Disturbance Question-
naire (BMDQ)[54]), support mechanisms and social
contact (using the Measure of Social and Recreational
Activities (MSRA))[55], duration of illness: measured in
weeks since event, and current medication and any
recent change to drug regimes, measured by patient and
carer self-reports, self reported co-morbidities and past
history of depression.
Randomisation
All eligible families will be randomly assigned to either
the DepReT-Stroke or TAU arm of the trial. Randomi-
sation will be undertaken by the Clinical Research Trials
Unit (CRTU) at the University of East Anglia (UEA).
Patients will be allocated a unique identification number
which will be sent to the trials unit, where allocation
will be carried out by permuted blocks of random size.
The treating nurse will be notified of the allocation and
arrange directly with the patient for the allocated treat-
ment to be given. The RA who conducts the baseline
interview and the follow-up assessment will remain
blind to allocation throughout the study to minimise
bias. The randomisation schedule will be designed by
the CRTU.
Intervention
Development of the DepReT-Stroke package
DepReT-Stroke is a comprehensive, evidence-based,
structured intervention with associated information in a
range of appropriate formats capable of being tailored
according to individual need and designed for delivery
by a trained nurse specialist. The intervention has been
developed by the research team in conjunction with
stroke, depression and education experts. Core aims of
the package are to facilitate shared decision making
between practitioners and people with stroke and/or
their carers with regard to the treatment of depression.
It will be offered as an adjunct and enhancer of TAU.
DepReT-Stroke will enable families to consider the
various treatment options for depression, make choices
about which are likely to fit best with their lives and
support them in the use of self-help therapies (e.g. com-
puterised CBT or exercise). An essential component of
the DepReT-Stroke package will be to help people
adhere to their chosen treatment(s) by enabling them to
explore possible ambivalence towards and beliefs about
antidepressive treatments (both psychological and phar-
macological). Sessions will focus on exchange of infor-
mation about therapy choices and facilitate reflection on
progress to date. The package will also be designed to
help the person in the family who may not be depressed
to adjust to life after a stroke, consider the possible risk
of depression in the future and provide them with tech-
niques to self monitor their mood. As aphasia is an
important predictor of carer strain, particular care will
be taken to design the DepReT-Stroke package in a
manner that is relevant for aphasic patients.
Description of the DepReT-Stroke package
The intervention will comprise six sessions with a
trained study nurse delivered at fortnightly intervals.
Each session will last approximately 30 minutes. In addi-
tion, two booster sessions will be delivered at three and
five months post randomisation. These sessions will
enable the nurse to monitor adherence, facilitate partici-
pants to reflect on progress and help them to adapt or
refine their chosen treatment strategies if required.
There will be a strong emphasis on facilitating home-
work tasks and self help activities. Risk of suicide will be
assessed at the beginning of each session and, if identi-
fied, the participant’s GP or the local crisis team will be
contacted. Completion of treatment will be defined as
attending a minimum of five out of eight sessions with
the nurse (including booster sessions). After the first 20
sessions the nurses who deliver the package will feed
back their experiences of delivering the DepReT-Stroke
package to the research team. If any gaps in information
or difficulties with format are identified, these will be
addressed before the remaining sessions are delivered.
Follow up
Baseline measures of efficacy will be repeated at six
months post randomisation; reflecting the recommended
duration of treatment for moderate to severe depres-
sion
2. The RA blinded for trial arm allocation will tele-
phone families to arrange a date to visit them at home
to obtaining follow up information.
Analysis
Description of Statistical Methods
Standard methods will be used to provide tabular and
graphical summaries as appropriate for continuous and
categorical variables.
Baseline analyses
To determine external generalisability, demographic and
clinical characteristics of participants’ responses at the
baseline phase of the study will be compared for partici-
pants who are subsequently randomised and participants
who are screened but not randomised using one-way
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ous variables and Fishers exact or Chi-squared test for
categorical variables, as appropriate. The specific criteria
by which participants are excluded from randomisation
will be tabulated. Demographic and clinical characteris-
tics will be compared between the intervention and con-
trol groups to identify any imbalances without statistical
testing [56].
Sample size
The cluster within this trial is the family (patient and
carer). We will need to analyse data from 102 indivi-
duals (i.e. 51 families) (approximately 51 individuals in
the DepReT-Stroke group and 51 individuals in the
TAU group). This will provide 80% power to detect,
with a significance level 5%, an overall difference
between intervention and TAU of 6 points in the SF-
36v2 MCS sub-scale with a standard deviation of the
MCS of 12 [57] equivalent to an effect size of 0.5SD.
The calculation assumes a clustering effect of scores by
family with a ICC of 0.05, and that the analysis would
adjust for baseline values, with a baseline-endpoint cor-
relation in MCS scores of 0.5. With an estimated 20%
attrition rate, this will require randomising 126 indivi-
duals at baseline. We pre-defined 0.5 SD (6 points) dif-
ference between intervention and TAU as this effect size
is clinically significant difference for stroke patients/
carers with depression [58].
Effectiveness analysis
The effectiveness of the intervention on the primary
outcome (MCS-SF-36v2) will be assessed by comparing
the mean change in values of DepReT-Stroke and TAU
groups from baseline to six month follow-up, adjusting
for the clustering effect of the family and the baseline
score. This will be achieved by analysis of covariance
with robust standard errors using the STATA statistical
software package (STATACORP LP, Texas, USA). The
effects of the intervention will be reported as change
scores. Appropriate adjustments will be made in the sta-
tistical analyses for prognostic factors, particularly those
unevenly distributed between the groups. Prognostic
strength will be checked with regression analyses and
only those with strongest effects on outcome used to
adjust the trial effects [59,60].
Both intention to treat (ITT) and per protocol (PP)
analyses will be performed. ITT analysis will be the pri-
mary analysis population and will be used for evaluation
of all endpoints.
Economic evaluation
In line with guidance from the National Institute for
Health and Clinical Excellence (NICE), costs will be cal-
culated from the perspective of the NHS and personal
social services and encompass those costs that are
potentially related to the intervention in question. We
will monitor the levels of resource use associated with
any re-admission to hospital and other health and non-
health care contacts (e.g. further therapy, nursing care,
social services). Patient and carer resource use will be
obtained from responses to a modified version of the
Client Service Receipt Inventory (CSRI) at baseline and
six months post randomisation. Appropriate unit costs
will subsequently be assigned in order to calculate total
costs for DepReT-Stroke and TAU.
The measures of effectiveness employed in the eco-
nomic analysis will be the EQ-5D [49]. This is a generic
measure of health status designed to compare the bene-
fits of different interventions. It has 5 dimensions -
mobility, self-care, usual activities, pain, anxiety and
depression. These will be used to calculate quality-
adjusted-life-years (QALYs) associated with the inter-
vention and TAU.
An economic model will be constructed in order to
estimate both the mean overall cost and effect associated
with both DepReT-Stroke and treatment as usual. If one
of these options were shown to be less costly and more
effective than the other then this would suggest that it
‘dominates’ the other, and represents a cost-effective use
of scarce resources. Alternatively, the incremental cost-
effectiveness ratio associated with DepReT-Stroke will be
estimated and assessed in relation to a range of cost-
effectiveness thresholds per QALY. The associated level
of uncertainty will also be characterised by estimating the
cost-effectiveness acceptability curve. Sensitivity analysis
will also be undertaken to assess the robustness of con-
clusions to changes in key assumptions.
Qualitative evaluation
Qualitative interviews will be undertaken with a purpo-
sively selected sub-sample of patients (n = 5) and carers
(n = 5) from the intervention group. A ‘short list’ of sui-
table participants will be compiled as follows. At the fol-
low up visit the researcher will enquire whether families
are still willing to undertake this element of the study. If
s o ,t h e yw i l lb ep l a c e di n t oo n eo ft h r e eg r o u p s( i . e .t h e
person with stroke is depressed, the carer is depressed
or both are depressed). Every second family in each
group will be selected and the researcher will arrange a
convenient time for another member of the research
team to visit. Interviews will be conducted in families’
homes in accordance with a defined schedule and take
approximately 30 minutes to complete. The aim of the
interviews will be to: obtain insights into families and
health professionals’ experiences of using the package;
consider which elements of the package were perceived
as being most and least helpful; explore the participants’
perceptions of the effect that they think the package (as
opposed to just the antidepressant treatment) has on
them; Uncover any potential barriers and roadblocks to
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refined and enhanced.
All interviews will be audio-recorded, transcribed ver-
batim and transcripts sent to participants for corrobora-
tion. Confirmed transcripts will be coded using thematic
analysis [61]. A summary of the results will then be
returned to participants for member checking [62]. If
the intended sample (n = 10) fails to provide a rounded
picture of delivering DepReT-Stroke, additional partici-
pants will be interviewed using the same methodology
as described until saturation is achieved. At the end of
the intervention phase, a similar interview will be con-
ducted with the nurse delivering DepReT-Stroke. This
will take place at the University of East Anglia at a
mutually convenient time.
Potential Bias
In order to compensate for any possible “researcher
bias” the following elements have been included in the
research design. A single nurse will deliver all DepReT-
Stoke sessions. The subjective nature of the self report
instruments used for evaluation of the intervention is
accepted and every effort will be made to minimise
potential bias due to this dynamic. In particular, people
with stroke and their carers may over or under report
health status depending on the trial arm to which they
have been assigned. The researcher who conducts the
baseline interview and the follow-up assessment will be
trained to administer questionnaires in a standardised
w a y .E v e r ye f f o r tw i l lb em a d et oe n s u r et h e yr e m a i n
blind to trial arm allocation throughout the study. At
the follow up meeting they will request that the family
do not mention whether they have seen the nurse or
not. However, economic evaluation data on use of
health services is likely to reveal trial arm allocation. For
this reason the researcher will obtain this information
after all other questionnaires have been completed.
Information regarding potential confounding factors
(listed above) will be collected at baseline. Qualitative
interviews will not be conducted with the first 5 families
in each sub-group (i.e. the person with stroke is
depressed, the carer is depressed or both are depressed)
in order to allow the intervention to settle.
Ethical considerations
The trial protocol was reviewed by a NHS Research
Ethics Committee (REC) and was approved from an ethi-
cal perspective (REC reference number: 10/H0310/23).
Discussion
Depression is a distressing and disabling illness and
commonly occurs after stroke in both patients and their
carers. Our DepReT-Stroke package aims to ensure that
families develop a better understanding of depression
and are able to choose a treatment that suits them and
they are comfortable sticking with. DepReT-Stroke is a
manualised intervention with the express intention that
if effective health professionals will be able to incorpo-
rate it into their practice with minimal training. We
need, however, to establish the efficacy and cost effec-
tiveness of the package using the most rigorous scienti-
fic approach.
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